SG3 Management’s Bristol-Myers Squibb BMY Stock Holding History

SG3 Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,200	Closed	-$511K	–	991
2021 Q4	$511K	Hold	8,200	–	–	0.01%	616
2021 Q3	$485K	Buy	+8,200	New	+$540K	0.01%	603
2021 Q2	–	Sell	-18,500	Closed	-$1.17M	–	1042
2021 Q1	$1.17M	Sell	18,500 -100,400	-84%	-$6.25M	0.03%	559
2020 Q4	$7.38M	Buy	118,900 +98,900	+495%	+$6.08M	0.14%	138
2020 Q3	$1.21M	Sell	20,000 -30,000	-60%	-$1.81M	0.04%	387
2020 Q2	$2.94M	Buy	50,000 +27,500	+122%	+$1.64M	0.2%	131
2020 Q1	$1.25M	Buy	+22,500	New	+$1.38M	0.17%	90
2019 Q4	–	Sell	-30,000	Closed	-$1.52M	–	265
2019 Q3	$1.52M	Hold	30,000	–	–	0.14%	102
2019 Q2	$1.36M	Sell	30,000 -30,500	-50%	-$1.42M	0.15%	124
2019 Q1	$2.89M	Buy	+60,500	New	+$3.01M	0.29%	79
2017 Q2	–	Sell	-11,900	Closed	-$647K	–	220
2017 Q1	$647K	Hold	11,900	–	–	0.12%	115
2016 Q4	$695K	Buy	+11,900	New	+$651K	0.11%	116

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

SG3 Management's BMY Position: Q2 2021 in Review

SG3 Management sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 250 shares — an estimated $16.3K sold.

SG3 Management first reported a position in BMY in Q1 2018 and held it in 7 quarters. The position peaked at $2.85M in Q1 2018. 2,369 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

SG3 Management reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 250 Bristol-Myers Squibb shares in Q2 2021, an estimated $16.3K.
SG3 Management first reported a position in Bristol-Myers Squibb in Q1 2018 and held it in 7 quarters.
SG3 Management's Bristol-Myers Squibb position peaked at $2.85M in Q1 2018.
2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.